2026-04-13T18:07:41Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/92722025-10-24T10:40:20Zcom_2072_378070com_2072_378040col_2072_378092

JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases Herrera de Guise, Claudia Maria Serra Ruiz, Xavier Lastiri Gonzalez, Ernesto Alejandro Borruel Sainz, Natalia Institut Català de la Salut Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Intestins - Inflamació - Tractament Proteïnes quinases - Inhibidors - Ús terapèutic DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas Otros calificadores::Otros calificadores::/uso terapéutico JAK inhibitors; Oral therapies; Small molecules Inhibidors de JAK; Teràpies orals; Molècules petites Inhibidores de JAK; Terapias orales; Moléculas pequeñas Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract that requires chronic treatment and strict surveillance. Development of new monoclonal antibodies targeting one or a few single cytokines, including anti-tumor necrosis factor agents, anti-IL 12/23 inhibitors, and anti-α4β7 integrin inhibitors, have dominated the pharmacological armamentarium in IBD in the last 20 years. Still, many patients experience incomplete or loss of response or develop serious adverse events and drug discontinuation. Janus kinase (JAK) is key to modulating the signal transduction pathway of several proinflammatory cytokines directly involved in gastrointestinal inflammation and, thus, probably IBD pathogenesis. Targeting the JAK-STAT pathway offers excellent potential for the treatment of IBD. The European Medical Agency has approved three JAK inhibitors for treating adults with moderate to severe Ulcerative Colitis when other treatments, including biological agents, have failed or no longer work or if the patient cannot take them. Although there are currently no approved JAK inhibitors for Crohn’s disease, upadacitinib and filgotinib have shown increased remission rates in these patients. Other JAK inhibitors, including gut-selective molecules, are currently being studied IBD. This review will discuss the JAK-STAT pathway, its implication in the pathogenesis of IBD, and the most recent evidence from clinical trials regarding the use of JAK inhibitors and their safety in IBD patients. 2023-03-30T10:00:03Z 2023-03-30T10:00:03Z 2023-03-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med. 2023 Mar 2;10:1089099. 2296-858X https://hdl.handle.net/11351/9272 10.3389/fmed.2023.1089099 36936239 http://hdl.handle.net/11351/9272 eng Frontiers in Medicine;10 https://doi.org/10.3389/fmed.2023.1089099 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Frontiers Media Scientia